ArticleApplied immunohistochemistry & molecular morphology : AIMM2026
Molecular Characterization of Biphasic Follicular Dendritic Cell Sarcoma.
Article in Applied immunohistochemistry & molecular morphology : AIMM, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Follicular dendritic cell sarcoma (FDCS) is a rare malignant neoplasm commonly found in extranodal sites with unclear pathogenesis. Tumor cells typically exhibit a spindled morphology, whereas epithelioid morphology is rarely reported. Here, we have presented a rare biphasic FDCS with distinct immunophenotypic and molecular characteristics. A 63-year-old female presented with constipation and rectal bleeding. Imaging revealed an 11.4 cm lobulated enhancing soft tissue mass in the posterior pelvis. H&E sections revealed 2 sharply demarcated biphasic neoplastic populations: one population comprised spindled cells expressing CD21, CD23, CD35, clusterin, EMA, and D2-40; the other population consisted of epithelioid cells lacking CD21 and other FDC-associated markers except for focal weak clusterin expression. Both populations tested negative for CD163, CD68, S-100, langerin, CD1a, ALK-1, CD30, CD117, HMB45, Pan-CK, and EBER. The tumor was initially misdiagnosed as a collision (FDCS and perivascular epithelioid cell tumor) tumor. Molecular studies revealed a nearly identical mutational profile in both components confirming clonal identity and ruling out a composite tumor. In addition, low-level pathogenic mutations (variant allele frequency <10%) were found in GABRA6 , ICOSLG , and VEGFA , alongside altered transcript expression in PDGFRB in both populations. Although no RNA fusions were detected, we demonstrated a significant increase in PDGFRB expression using the RNA Salah Targeted Expression panel, with a log 2 ratio > 2, indicating a more than 4-fold increase compared with a pooled normal control. Here, we have provided molecular characterization of biphasic FDCS. Prior such characterization seems to be unavailable in the literature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.